Patient oriented Research--Colon CA & Cancer Immunology

描述（由申请人提供）：本申请详细说明了经验， 资格和短期和长期计划，以病人为导向 研究和指导活动的兰德尔F。Holcombe，MD，首席 加州大学欧文分校血液学/肿瘤学 赵氏综合癌症中心临床研究主任。 自1989年完成血液学/肿瘤学专科培训以来， Holcombe博士在临床和翻译领域建立了学术生涯 以患者为导向的研究，包括临床和基础研究， 肿瘤学、免疫学和遗传学领域。 他成功地在 开展临床/转化试验和获得校外支持 对于这些活动。 在过去的几年里，他还 积极指导刚开始的临床研究者。 本申请 在以患者为导向的研究中，职业中期研究者奖将提供 支持Holcombe博士继续并扩大这些活动。 此应用程序将概述拟议的研究和指导活动， 对这些活动的机构支持，以及 霍尔科姆博士致力于以病人为导向的研究。 这是第二次修订的中期职业调查奖， 以患者为导向的研究（K24）最初于1998年10月1日提交， 1999年7月1日提交修订。 针对问题进行了实质性修改 第一次简要说明中提出的问题已纳入第一次修订。 虽然在第二份摘要中注意到对该提案的批评很少， 声明中，进一步加强应用程序的其他信息 在准备第二次修订时提供。

DESCRIPTION (provided by applicant): This application details the experience, qualifications and short- and long-term plans for the patient-oriented research and mentoring activities of Randall F. Holcombe, MD, Chief of Hematology/Oncology at the University of California, Irvine and Associate Director for Clinical Research of the Chao Family Comprehensive Cancer Center. Since completion of Hematology/Oncology sub-specialty training in 1989, Dr. Holcombe has established an academic career in clinical and translational patient-oriented research involving both clinical and basic investigations in the areas of oncology, immunology and genetics. He has been successful in conducting clinical/translational trials and in obtaining extramural support for these activities. Currently and over the past several years, he has also been active in mentoring beginning clinical investigators. This application for the Midcareer Investigator Award in Patient-Oriented Research will provide support to allow Dr. Holcombe to continue and expand upon these activities. This application will outline proposed research and mentoring activities, institutional support for these activities, and documentation of Dr. Holcombe's commitment to a career in patient-oriented research. This is a second revision of a Midcareer Investigator Award in Patient-Oriented Research (K24) initially submitted 10/1/98, with a first revision submitted 7/1/99. Substantial modifications in response to questions raised in the first summary statement were included in the first revision. While minimal criticisms of the proposal were noted in the second summary statement, additional information that further strengthens the application has been provided in preparation of this second revision.